Goldstein SR. Postmenopausal adnexal cysts: how clinical management has evolved. Am J Obstet Gynecol. 1996;175:1498–501.

Article  CAS  PubMed  Google Scholar 

Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–29.

Article  CAS  PubMed  Google Scholar 

Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol. 2001;81(3):398–403.

Article  CAS  PubMed  Google Scholar 

Winter WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2008;26:83–9.

Article  PubMed  Google Scholar 

Kok NF, Hingh IH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases of colorectal origin. Br J Surg. 2017;104(4):313–5.

Article  CAS  PubMed  Google Scholar 

Van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic Intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230–40.

Article  PubMed  Google Scholar 

Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(12):1578–89.

Article  CAS  PubMed  Google Scholar 

Elias D, Mariani A, Cloutier AS, Blot F, Goéré D, et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol. 2014;40(11):1467–73.

Article  CAS  PubMed  Google Scholar 

Fagotti A, Vizzielli G, De Iaco P, et al. A multicentric trial (Olympiae MITO13) on the accuracy of laparoscopy to assess peritoneal spread in ovarian cancer. Am J Obstet Gynecol. 2013;209(462):e1-11.

Google Scholar 

Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.

Article  CAS  PubMed  Google Scholar 

Sugarbaker PH, Chang D, Koslowe P. Prognostic features for peritoneal carcinomatosis in colorectal and appendiceal cancer patients when treated by cytoreductive surgery and intraperitoneal chemotherapy. Cancer Treat Res. 1996;81:89–104.

Article  CAS  PubMed  Google Scholar 

Llueca A, Serra A, Rivadulla I, Gomez L, Escrig J. group Mw. Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index. World J Surg Oncol. 2018;16:37.

Article  PubMed  PubMed Central  Google Scholar 

Halkia E, Spiliotis J, Sugarbaker P. Diagnosis and management of peritoneal metastases from ovarian cancer. Gastroenterol Res Pract. 2012;2012: 541842.

Article  PubMed  PubMed Central  Google Scholar 

Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol. 1999;43:15–25.

Article  Google Scholar 

Jónsdóttir B, Lomnytska M, Poromaa IS, Silins I, Stålberg K. The peritoneal cancer index is a strong predictor of incomplete cytoreductive surgery in ovarian cancer. Ann Surg Oncol. 2021;28(1):244–51.

Article  PubMed  Google Scholar 

Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2015;41:1578–89.

Article  CAS  PubMed  Google Scholar 

Elias D, Mariani A, Cloutier AS, et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol. 2014;40:1467–73.

Article  CAS  PubMed  Google Scholar 

Fagotti A, Ferrandina G, Fanfani F, et al. Prospective validation of a laparoscopic predictive model for optimal cytoreduction in advanced ovarian carcinoma. Am J Obstet Gynecol. 2008;199:642.e1-642.e6.

Article  PubMed  Google Scholar 

Engbersen MP, Lok C, Lambregts DMJ, Sonke GS, et al. MRI with diffusion-weighted imaging to predict feasibility of complete cytoreduction with the peritoneal cancer index (PCI) in advanced stage ovarian cancer patients. Eur J Radiol. 2019;114:146–51.

Article  CAS  PubMed  Google Scholar 

Torkzad M, Casta N, Bergman A, Ahlstro H, Hlman P, Mahteme H. Comparison between MRI and CT in prediction of peritoneal carcinomatosis index (PCI) in patients undergoing cytoreductive surgery in relation to the experience of the radiologist. J Surg Oncol. 2015;111:746–51.

Article  CAS  PubMed  Google Scholar 

Mazzei MA, Khader L, Cirigliano A, et al. Accuracy of MDCT in the preoperative definition of peritoneal cancer index (PCI) in patients with advanced ovarian cancer who underwent peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Abdom Imaging. 2013;38:1422–30.

Article  PubMed  Google Scholar 

Faron M, Macovei R, Goere D, Honore C, Benhaim L, Elias D. Linear relationship of peritoneal cancer index and survival in patients with peritoneal metastases from colorectal cancer. Ann Surg Oncol. 2016;23:114–9.

Article  PubMed  Google Scholar 

Simkens GA, Rovers KP, Nienhuijs SW, de Hingh IH. Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer. Cancer Manag Res. 2017;9:259–66.

Article  PubMed  PubMed Central  Google Scholar 

Tentes AAK, Tripsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. JSO. 2003;29:69–73.

Google Scholar 

Jonsdottir B, Lomnytska M, Poromaa IS, Silins I, Stalberg K. The peritoneal cancer index is a strong predictor of incomplete cytoreductive surgery in ovarian cancer. Ann Surg Oncol. 2021;28:244–51.

Article  PubMed  Google Scholar 

Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T. Neoadjuvant Chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.

Article  CAS  PubMed  Google Scholar 

Sironi S, Messa C, Mangili G, Zangheri B, Aletti G, Garavaglia E, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology. 2004;233:433–40.

Article  PubMed  Google Scholar 

Torizuka T, Nobezawa S, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging. 2002;29:797–803.

Article  CAS  PubMed  Google Scholar 

De Vos N, Goethals I, Ceelen W. Clinical value of (18)F-FDG- PET-CT in the preoperative staging of peritoneal carcinomatosis from colorectal origin. Acta Chir Belg. 2014;114(6):370–5.

Article  PubMed  Google Scholar 

Berthelot C, Morel O, Girault S, Verrièle V, Poirier A-L, Moroch J, Boucher Y, Le Jeune J-J, Lorimier G. Use of FDG-PET/CT for peritoneal carcinomatosis before hyperthermic intraperitoneal chemotherapy. Nucl Med Commun. 2011;32(1):23–9.

Article  PubMed  Google Scholar 

Dromain C, Leboulleux S, Auperin A, Goere D, Malka D, Lumbroso J, et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT Jan-Feb. 2008;33(1):87–93.

Google Scholar 

Elekonawo FM, Starremans B, Laurens ST, Bremers AJ, De Wilt JH, Heijmen L, de Geus-Oei LF. Can [ 18 F]F-FDG PET/CT be used to assess the pre-operative extent of peritoneal carcinomatosis in patients with colorectal cancer? Abdom Radiol. 2020;45(2):301–6.

Article  Google Scholar 

Cascales-Campos PA, Álvaro Jesús GR, José G, Elena G, Pascual P, et al. Validation of a peritoneal surface disease severity score in stage IIIC-IV ovarian cancer treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Surg Oncol. 2019;28:57–61.

Article  Google Scholar